RecruitingObservational

Molecular Analysis of Suspected or High-Risk Lung Cancer to Drive Individualized Care (Interception for Suspected Lung Cancer)

NCT ID: NCT06482073Sponsor: Mayo ClinicLast updated: 2026-02-27

Summary

This study evaluates the effectiveness of robotic biopsies in providing information about hereditary or cancer specific genetic variants that may have a role in diagnosis of cancer and to develop genetic results and medical record databank for future studies.

Detailed description

PRIMARY OBJECTIVES: I. Assessing whether the percentage of samples adequate for WES (Whole Exome Sequencing)/WT (Wild-Type) sequencing is at least 80%. II. Development of a data bank of WES/WT and germline sequencing data for future analyses. OUTLINE: This is an observational study. Patients receive genomic counseling and genomic testing education, undergo blood or saliva collection, provide previously collected tissue sample and have medical records reviewed on study. Patients and healthcare providers receive results of any genetic variants found on testing.

Arms & interventions

OtherNon-Interventional Study
Non-interventional study

Outcome measures

Primary

Percent of samples adequate for sequencing
Assessed based on the number of tissue samples determined to be adequate for WES (Whole Exome Sequencing)/WT (wild-type) sequencing.
Time frame: Up to 2 years

Secondary

Data bank of genomic data
Time frame: Up to 2 years

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No

Inclusion Criteria: * Subject age 18 years and older * Subject is scheduled/was scheduled for a bronchoscopy as part of standard of care * Subject with a moderate to high risk of lung cancer based on clinical demographic and radiologic information or with suspected metastatic disease * Ability to provide blood or saliva sample * Ability to provide archived tissue * Subject is able to understand and adhere to study requirements and able to provide informed consent Exclusion Criteria: * Individuals who have situations that would limit compliance with the study requirements * Institutionalized (i.e. federal medical prison) * Pregnant * Prior germline genetic testing with a 40+ multi-gene panel within the last 1 year of enrollment * Prior somatic tissue (250+ gene) testing within the prior 3 months of enrollment

Study locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, 55905

Recruiting

Clinical Trials Referral Office · Contact

855-776-0015 mayocliniccancerstudies@mayo.edu

Janani S. Reisenauer, M.D. · Principal Investigator